TY - JOUR T1 - Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study JF - medRxiv DO - 10.1101/2020.08.04.20168203 SP - 2020.08.04.20168203 AU - Shiwani Mahajan AU - Rajesh Srinivasan AU - Carrie A. Redlich AU - Sara K. Huston AU - Kelly M. Anastasio AU - Lisa Cashman AU - Dorothy S. Massey AU - Andrew Dugan AU - Dan Witters AU - Jenny Marlar AU - Shu-Xia Li AU - Zhenqiu Lin AU - Domonique Hodge AU - Manas Chattopadhyay AU - Mark D. Adams AU - Charles Lee AU - Lokinendi V. Rao AU - Chris Stewart AU - Karthik Kuppusamy AU - Albert I. Ko AU - Harlan M. Krumholz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/25/2020.08.04.20168203.abstract N2 - Background A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population, however, most existing reports have used a convenience sample, which may bias their estimates.Methods We sought a representative sample of Connecticut residents, aged ≥18 years and residing in non-congregate settings, who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 29, 2020. We also oversampled non-Hispanic Black and Hispanic subpopulations. We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies and the prevalence of symptomatic illness and self-reported adherence to risk mitigation behaviors among this population.Results Of the 567 respondents (mean age 50 [±17] years; 53% women; 75% non-Hispanic White individuals) included at the state-level, 23 respondents tested positive for SARS-CoV-2-specific antibodies, resulting in weighted seroprevalence of 4.0 (90% confidence interval [CI] 2.0–6.0). The weighted seroprevalence for the oversampled non-Hispanic Black and Hispanic populations was 6.4% (90% CI 0.9–11.9) and 19.9% (90% CI 13.2–26.6), respectively. The majority of respondents at the state-level reported following risk mitigation behaviors: 73% avoided public places, 75% avoided gatherings of families or friends, and 97% wore a facemask, at least part of the time.Conclusions These estimates indicate that the vast majority of people in Connecticut lack antibodies against SARS-CoV-2 and there is variation by race/ethnicity. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents to prevent resurgence of COVID-19 in this region.Competing Interest StatementDr. Lee is an Adjunct Professor at The First Affiliated Hospital of Xian Jiaotong University. Dr. Ko reports grants from Bristol Myer Squib Foundation, Regeneron, and Serimmune, and honoraria from Bristol Myer Squib, outside the submitted work. Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the United States Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; is a consultant to FPrime; is a co-founder of HugoHealth, a personal health information platform; and is a co-founder of Refactor Health, an enterprise healthcare artificial intelligence-augmented data management company. The other co-authors report no potential competing interests.Funding StatementThis project was supported by the Centers for Disease Control and Prevention through the CARES Act and the Beatrice Kleinberg Neuwirth Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was deemed not to be research by the Institutional Review Board at Yale University because of the public health surveillance activity exclusion and was approved by the Institutional Review Board at Gallup.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A ER -